Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

Rhea-AI Summary

Armata Pharmaceuticals (NYSE American: ARMP) will participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage, scheduled for November 30, 2022, from 10:00-10:30 AM EST. This conference will be held virtually, focusing on the company's advancements in bacteriophage therapeutics aimed at treating antibiotic-resistant infections. Armata is developing a diverse pipeline of phage candidates, particularly for Pseudomonas aeruginosa and Staphylococcus aureus, and collaborates with Merck on synthetic phage candidates.

MARINA DEL REY, Calif., Nov. 28, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the company will participate in the H.C. Wainwright 1^st Annual Investor Conference on Bacteriophage, which is being held virtually on November 30, 2022.

Armata's presentation is scheduled for 10:00-10:30 AM EST.

More information, including a registration link, can be found here.

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing. 

Media Contacts:

At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
310-665-2928 x234

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-participate-in-the-hc-wainwright-1st-annual-investor-conference-on-bacteriophage-301685297.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

When will Armata Pharmaceuticals participate in the H.C. Wainwright conference?

Armata Pharmaceuticals will participate in the H.C. Wainwright conference on Bacteriophage on November 30, 2022.

What time is Armata Pharmaceuticals' presentation at the conference?

Armata Pharmaceuticals' presentation is scheduled for 10:00-10:30 AM EST.

What is the focus of Armata Pharmaceuticals at the conference?

Armata Pharmaceuticals will focus on its bacteriophage therapeutics for antibiotic-resistant bacterial infections.

What are some pathogens Armata Pharmaceuticals is targeting?

Armata Pharmaceuticals is developing therapeutics targeting Pseudomonas aeruginosa and Staphylococcus aureus.

Is Armata Pharmaceuticals collaborating with any other companies?

Yes, Armata Pharmaceuticals is collaborating with Merck to develop synthetic phage candidates.